Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Publication | Open Access

DOI Full Paper Access

136

Citations

References

2022

Year

Sacha J. Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Siân Morgan, Magdalena Meissner, C. Bale, Pavel Bezecny, Sarah Moon,

The Lancet Oncology

Abstract

References